- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07619898
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure (PHOENIX-ECP)
PHOENIX- A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis or Hepatitis With Inadequate Response to Corticosteroids in Participants With Unresectable or Metastatic Melanoma Treated With Immune Checkpoint Inhibitors (ICI)
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.
Immune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately.
The purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to corticosteroids, and to compare its efficacy to other second-line immunosuppressant therapies. The ECP procedure in this study is performed using the CELLEX® device, a fully closed-loop extracorporeal blood circulation device. The CELLEX device is used in conjunction with methoxsalen.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Therakos TKS2001 Study Team
- Numéro de téléphone: 855-512-3327
- E-mail: Clinicaltrials@therakos.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Participants diagnosed with unresectable or metastatic melanoma ( Stage III and Stage IV) received ICI treatment (e.g., anti-PD-1, anti-PD-L1, anti-LAG-3, anti-CTLA-4 antibody, as ICI monotherapy or ICI combination therapy) and ICI paused or discontinued because of the development of ir-colitis or ir-hepatitis.
- Participants diagnosed with ir-colitis and/or ir-hepatitis with a severity of Grade 2 or higher, based on ASCO Guidelines (
- Participants with endoscopic evidence of ir-colitis
- Participants with inadequate response to corticosteroids, as defined per protocol
- Participants who have Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
Exclusion Criteria:
- Presence of irAEs in addition to and other than ir-colitis and/or ir-hepatitis, with a higher severity grade than the irAE for inclusion (ir-colitis/ir-hepatitis) based on ASCO guidelines.
- Participant has a diagnosis of uveal melanoma as the sole melanoma subtype
- Treatment of ir-colitis or ir-hepatitis with any systemic therapy other than corticosteroids
- Concurrent conditions which may require treatment with high dose corticosteroid (> 1 milligram per kilogram per day [mg/kg/day]) and interfere with the corticosteroid tapering schedule recommended by the protocol.
- Pre-existing liver disease
- Active alcohol use disorder
- Concomitant treatment with any chemotherapy or targeted therapy for the treatment of unresectable or metastatic melanoma.
- Use of any investigational agent within 5 half-lives of the investigational agent prior to randomization.
- Contraindications or known allergic reaction to any of study intervention and/or procedures
- Participants unable to tolerate the fluid shift associated with the ECP procedure.
- Positive result for active or previous viral infections: covid-19, hepatitis B/C, CMV, EBV, adenovirus
- History of previous or concurrent malignancies within the last 3 years, other than unresectable or metastatic melanoma.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Methoxsalen in Conjunction with Extracorporeal Photopheresis System (ECP)
Participants will receive methoxsalen, in conjunction with ECP
|
Sterile solution used in conjunction with CELLEX ECP
Autres noms:
Methoxsalen is used in conjunction with the CELLEX ECP
Autres noms:
|
|
Comparateur actif: Best Available Therapy (BAT)
Participants with ir-colitis will receive either Infliximab or Vedolizumab as per the investigator's choice.
Participants with ir-hepatitis will receive Mycophenolate Mofetil (MMF) or Azathioprine as per the investigator's choice.
|
Vedolizumab will be administered intravenously
Infliximab will be administered intravenously
Mycophenolate Mofetil will be administered orally or intravenously
Azathioprine will be administered orally or intravenously
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Proportion of Participants Who are in Steroid-free response at Week 12 for the Randomized Immune-related Adverse Event (irAE) (ir-colitis or ir-hepatitis)
Délai: Week 12
|
Week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Duration of irAE response
Délai: Week 64
|
Time from the start of irAE response to either the relapse of irAE (if relapse occurs), or a censoring event.
|
Week 64
|
|
Progression Free Survival (PFS) for Melanoma
Délai: Week 64
|
Week 64
|
|
|
Overall Survival (OS)
Délai: Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least Stable Disease as Assessed by RECIST 1.1 at Week 12 and During Follow-up
Délai: Week 12 and Week 64
|
Week 12 and Week 64
|
|
|
Proportion of Participants with Treatment-Emergent Adverse Event (TEAEs) per Common Toxicity Criteria for Adverse Events (CTCAE) v5.0
Délai: From first dose of the study drug up to end of study (up to Week 64)
|
From first dose of the study drug up to end of study (up to Week 64)
|
|
|
Cumulative Systemic Corticosteroid Exposure From Randomization to Week 12
Délai: Up to Week 12
|
Up to Week 12
|
|
|
Peak Dose of Systemic Corticosteroid Exposure From Randomization to Week 12
Délai: Up to Week 12
|
Up to Week 12
|
|
|
Proportion of Participants who Completely Discontinue Systemic Corticosteroid Treatment Until Week 12
Délai: Week 12
|
Week 12
|
|
|
Time to Complete Discontinuation of Systemic Corticosteroids for at Least 1 Week
Délai: From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
|
|
Time to First Response of Randomized irAE Based on ASCO Criteria
Délai: Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least one irAE who Achieve Response (as Defined per ASCO Criteria) at Week 12
Délai: Week 12
|
Week 12
|
|
|
Proportion of Participants With at Least One irAE That Resolves Completely (as per CTCAE v5.0) and Remains Resolved Until Week 12
Délai: Week 12
|
Week 12
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Isabelle T Seemann, Ph.D, Therakos LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Essai contrôlé randomisé
- Mélanome
- Dispositif
- Mélanome métastatique
- Mélanome non résécable
- ECP
- Colite
- Événements indésirables liés au système immunitaire
- Colite liée au système immunitaire
- Essai clinique de phase 2
- Photophérèse extracorporelle
- Méthoxsalène
- Réfractaire aux stéroïdes
- Immune checkpoint inhibitor toxicity
- Checkpoint inhibitor-induced colitis
- Checkpoint inhibitor-induced hepatitis
- Immune checkpoint Inhibitors
- UVADEX
- Corticosteroid refractory
- Cellex
- 8-Mop
- Ir-AE
- Ir-AE Colitis
- Ir-AE Hepatitis
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs par type histologique
- Maladies du système digestif
- Maladies gastro-intestinales
- Maladies du foie
- Maladies du côlon
- Maladies de la peau
- Gastro-entérite
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Tumeurs cutanées
- Maladies de la peau et du tissu conjonctif
- Hépatite
- Colite
- Mélanome
- Acides aminés, peptides et protéines
- Protéines
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Thérapeutique
- Pyrans
- Acides gras
- Lipides
- Procédures chirurgicales, opératoires
- Acides nucléiques, nucléotides et nucléosides
- Acides, acyclique
- Acides carboxyliques
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Purines
- Nucléosides
- Coumarines
- Benzopyrans
- Caproates
- Photothérapie
- Composés hétérocycliques, 3 ring
- Circulation extracorporelle
- Thérapie PUVA
- Thérapie ultraviolette
- Furocoumarines
- Thionucléosides
- Mercaptopurine
- Infliximab
- Acide mycophénolique
- Azathioprine
- Méthoxsalène
- vedolizumab
- Photopherèse
Autres numéros d'identification d'étude
- TKS2001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .